中华皮肤科杂志 ›› 2018, Vol. 51 ›› Issue (7): 552-554.doi: 10.3760/cma.j.issn.0412-4030.2018.07.026
• 综述 • 上一篇
孙艳1,江世宾1,郭宏佐1,肖碧环2,高兴华2,吴严1
收稿日期:2017-06-02
修回日期:2017-07-25
发布日期:2018-06-29
通讯作者:
吴严
E-mail:jlwuyan@126.com
Yan SUN1,Shi-Bin JIANG1, 1,xiaobi huan2, 2,
Received:2017-06-02
Revised:2017-07-25
Published:2018-06-29
摘要： 玫瑰痤疮是一种发生在颜面中部的慢性炎症性皮肤病，临床分为4型：红斑毛细血管扩张型、丘疹脓疱型、肥大增生型、眼型，其中红斑毛细血管扩张型最为常见。由于本病发生于面部，除了对患者生理造成一定影响，部分患者还会产生心理问题。玫瑰痤疮治疗是一个长期复杂的过程，我们就其治疗进展综述如下……
孙艳 江世宾 郭宏佐 肖碧环 高兴华 吴严. 玫瑰痤疮的治疗进展[J]. 中华皮肤科杂志, 2018,51(7):552-554. doi:10.3760/cma.j.issn.0412-4030.2018.07.026
Yan SUN Shi-Bin JIANG xiaobi huan. Treatment of acne rosacea[J]. Chinese Journal of Dermatology, 2018, 51(7): 552-554.doi:10.3760/cma.j.issn.0412-4030.2018.07.026
| ［1］ | 中国医师协会皮肤科医师分会皮肤美容亚专业委员会. 中国玫瑰痤疮诊疗专家共识（2016）［J］. 中华皮肤科杂志, 2017,50（3）:156⁃161. doi: 10.3760/cma.j.issn.0412⁃4030.2017.03.002.<br /> |
| ［2］ | Two AM, Wu W, Gallo RL, et al. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea［J］. J Am Acad Dermatol, 2015,72（5）:761⁃770; quiz 771⁃772. doi: 10.1016/j.jaad. 2014.08.027.<br /> |
| ［3］ | Del RJQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies［J］. Cutis, 2014,93（1）:18⁃28.<br /> |
| ［4］ | Tüzün Y, Wolf R, Kutlubay Z, et al. Rosacea and rhinophyma［J］. Clin Dermatol, 2014,32（1）:35⁃46. doi: 10.1016/j.clindermatol. 2013. 05.024.<br /> |
| ［5］ | van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea［J］. Cochrane Database Syst Rev, 2015,（4）:CD003262. doi: 10.1002/14651858.CD003262.pub5.<br /> |
| ［6］ | Sobolewska B, Doycheva D, Deuter C, et al. Treatment of ocular rosacea with once⁃daily low⁃dose doxycycline［J］. Cornea, 2014,33（3）:257⁃260. doi: 10.1097/ICO.0000000000000051.<br /> |
| ［7］ | Reinholz M, Tietze JK, Kilian K, et al. Rosacea ⁃ S1 guideline［J］. J Dtsch Dermatol Ges, 2013,11（8）:768⁃780. doi: 10. 1111/ddg. 12101.<br /> |
| ［8］ | Abokwidir M, Feldman SR. Rosacea management［J］. Skin Appendage Disord, 2016,2（1⁃2）:26⁃34. doi: 10.1159/000446215.<br /> |
| ［9］ | Akhyani M, Ehsani AH, Ghiasi M, et al. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial［J］. Int J Dermatol, 2008,47（3）:284⁃288. doi: 10.1111/j.1365⁃4632.2008.03445.x.<br /> |
| ［10］ | Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR⁃2⁃mediated innate immune responses in acne patients［J］. J Invest Dermatol, 2012,132（9）:2198⁃2205. doi: 10.1038/jid.2012.111.<br /> |
| ［11］ | Rademaker M. Very low⁃dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients［J］. Australas J Dermatol, 2018,59（1）:26⁃30. doi: 10.1111/ajd.12522.<br /> |
| ［12］ | Gollnick H, Blume⁃Peytavi U, Szabó EL, et al. Systemic isotretinoin in the treatment of rosacea ⁃ doxycycline⁃ and placebo⁃controlled, randomized clinical study［J］. J Dtsch Dermatol Ges, 2010,8（7）:505⁃515. doi: 10.1111/j.1610⁃0387.2010.07345.x.<br /> |
| ［13］ | Wee JS, Tan KB. Phymatous rosacea presenting with leonine facies and clinical response to isotretinoin［J］. Australas J Dermatol, 2017,58（1）:72⁃73. doi: 10.1111/ajd.12505.<br /> |
| ［14］ | Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea［J］. Arch Dermatol, 2011,147（11）:1258⁃1260. doi: 10.1001/archdermatol.2011.204.<br /> |
| ［15］ | Layton A, Thiboutot D. Emerging therapies in rosacea［J］. J Am Acad Dermatol, 2013,69（6 Suppl 1）:S57⁃S65. doi: 10.1016/j.jaad. 2013.04.041.<br /> |
| ［16］ | 袁斌, 陈志健, 王炼. 硫酸羟氯喹联合0.1％他克莫司软膏治疗红斑毛细血管扩张型玫瑰痤疮疗效观察［J］. 临床合理用药杂志, 2016,9（31）:74⁃75. doi: 10.15887/j.cnki.13⁃1389/r.2016.31. 048.<br /> |
| ［17］ | Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15 gel［J］. J Am Acad Dermatol, 2013,69（4）:570⁃577. doi: 10.1016/j.jaad.2013.05.019.<br /> |
| ［18］ | Thiboutot DM, Fleischer AB, Del RJQ, et al. Azelaic acid 15 gel once daily versus twice daily in papulopustular rosacea［J］. J Drugs Dermatol, 2008,7（6）:541⁃546.<br /> |
| ［19］ | Salem DA, El⁃Shazly A, Nabih N, et al. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin⁃metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum［J］. Int J Infect Dis, 2013,17（5）:e343⁃347. doi: 10.1016/j.ijid.2012.11.022.<br /> |
| ［20］ | de Ménonville S T, Rosignoli C, Soares E, et al. Topical treatment of rosacea with ivermectin inhibits gene of cathelicidin innate immune mediators, LL⁃37 and KLK5, in reconstructed and ex vivo skin models［J］. Dermatol Ther （Heidelb）, 2017,7（2）:213⁃225. doi: 10.1007/s13555⁃017⁃0176⁃3.<br /> |
| ［21］ | Siddiqui K, Stein GL, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta⁃analysis［J］. Springerplus, 2016,5（1）:1151. doi: 10.1186/s40064⁃016⁃2819⁃8.<br /> |
| ［22］ | Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea［J］. J Eur Acad Dermatol Venereol, 2009,23（2）:239⁃240. doi: 10.1111/j.1468⁃3083.2008.02822.x.<br /> |
| ［23］ | El⁃Heis S, Buckley DA. Rosacea⁃like eruption due to topical pimecrolimus［J/OL］. Dermatol Online J, 2015,21（5）. pii: 13030/qt7kd1048m［2017⁃05⁃25］. https://cloudfront.escholarship.org/dist/prd/content/qt7kd1048m/qt7kd1048m.pdf?t=o41bak.<br /> |
| ［24］ | Hu L, Alexander C, Velez NF, et al. Severe tacrolimus⁃induced granulomatous rosacea recalcitrant to oral tetracyclines［J］. J Drugs Dermatol, 2015,14（6）:628⁃630.<br /> |
| ［25］ | Moore A, Kempers S, Murakawa G, et al. Long⁃term safety and efficacy of once⁃daily topical brimonidine tartrate gel 0.5 for the treatment of moderate to severe facial erythema of rosacea: results of a 1⁃year open⁃label study［J］. J Drugs Dermatol, 2014,13（1）:56⁃61.<br /> |
| ［26］ | Jackson JM, Fowler J, Moore A, et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea［J］. J Drugs Dermatol, 2014,13（6）:699⁃704.<br /> |
| ［27］ | Holmes AD, Waite KA, Chen MC, et al. Dermatological adverse events associated with topical brimonidine gel 0.33 in subjects with erythema of rosacea: a retrospective review of clinical studies［J］. J Clin Aesthet Dermatol, 2015,8（8）:29⁃35.<br /> |
| ［28］ | Kassir R, Kolluru A, Kassir M. Intense pulsed light for the treatment of rosacea and telangiectasias［J］. J Cosmet Laser Ther, 2011,13（5）:216⁃222. doi: 10.3109/14764172.2011.613480.<br /> |
| ［29］ | Liu J, Liu J, Ren Y, et al. Comparative efficacy of intense pulsed light for different erythema associated with rosacea［J］. J Cosmet Laser Ther, 2014,16（6）:324⁃327. doi: 10.3109/14764172.2014. 957218.<br /> |
| ［30］ | Baek JO, Hur H, Ryu HR, et al. Treatment of erythemato⁃telangiectatic rosacea with the fractionation of high⁃fluence, long⁃pulsed 595⁃nm pulsed dye laser［J］. J Cosmet Dermatol, 2017,16（1）:12⁃14. doi: 10.1111/jocd.12284.<br /> |
| ［31］ | Say EM, Okan G, Gökdemir G. Treatment outcomes of long⁃pulsed Nd: YAG laser for two different subtypes of rosacea［J］. J Clin Aesthet Dermatol, 2015,8（9）:16⁃20.<br /> |
| ［32］ | Alam M, Voravutinon N, Warycha M, et al. Comparative effectiveness of nonpurpuragenic 595⁃nm pulsed dye laser and microsecond 1064⁃nm neodymium:yttrium⁃aluminum⁃garnet laser for treatment of diffuse facial erythema: a double⁃blind randomized controlled trial［J］. J Am Acad Dermatol, 2013,69（3）:438⁃443. doi: 10.1016/j.jaad.2013.04.015.<br /> |
| ［33］ | Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients［J］. Br J Dermatol, 2009,161（4）:814⁃818. doi: 10.1111/j.1365⁃2133.2009.09317.x.<br /> |
| ［34］ | Serowka KL, Saedi N, Dover JS, et al. Fractionated ablative carbon dioxide laser for the treatment of rhinophyma［J］. Lasers Surg Med, 2014,46（1）:8⁃12. doi: 10.1002/lsm.22184.<br /> |
| ［35］ | 吴晓瑾, 陈向东, 费烨, 等. 光动力疗法治疗酒渣鼻的疗效［J］.中华医学美学美容杂志, 2014,20（1）:36⁃39. doi: 10.3760/cma.j.issn.1671⁃0290.2014.01.010.<br /> |
| ［36］ | 刘伟, 袁丹, 王倩, 等. 利用光纤导入组织内光动力疗法治疗酒渣鼻15例疗效观察与分析［J］. 中国美容医学, 2015,24（19）:41⁃44.<br /> |
| ［37］ | Friedmann DP, Goldman MP, Fabi SG, et al. Multiple sequential light and laser sources to activate aminolevulinic acid for rosacea［J］. J Cosmet Dermatol, 2016,15（4）:407⁃412. doi: 10.1111/jocd. 12231.<br /> |
| ［38］ | Prado R, Funke A, Bingham J, et al. Treatment of severe rhino⁃phyma using scalpel excision and wire loop tip electrosurgery［J］. Dermatol Surg, 2013,39（5）:807⁃810. doi: 10.1111/dsu.12193.w.<br /> |
| [1] | 孙小洁 刘毅. 抗雄激素药物治疗皮肤病研究进展[J]. 中华皮肤科杂志, 2023, 56(9): 882-885. |
| [2] | 王钰倩 乔建军 方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2023, 56(9): 885-888. |
| [3] | 刘元香 梁源 赵欣荣 孙玉娟 马琳 徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023, 56(9): 849-852. |
| [4] | 袁心刚 倪思利 张建 罗晓燕 王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786. |
| [5] | 钟洁敏 邵蕾 梁毅敏 黄琼霄 夏曼琪 刘玉梅. 射频火针与光动力疗法治疗面部中重度痤疮炎性皮损的疗效与安全性对比研究[J]. 中华皮肤科杂志, 2023, 56(8): 751-755. |
| [6] | 宋志强 陈奇权 葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723. |
| [7] | 王俊霞 郭伟楠 陈慧 郝军峰 李冰 卫静宜 赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765. |
| [8] | 陈小敏 张景展 丁媛 康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802. |
| [9] | 周彤 耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793. |
| [10] | 李越 吴金燕 袁若月 杨屈杨 赵贤省 朱宁文. 细胞治疗遗传性大疱性表皮松解症研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 698-702. |
| [11] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625. |
| [12] | 米淑宏 余艳琴 郝金奇 李薇 张杨 贾喜梅 黄毓娴 孙怀玉 石继海. 丘疹脓疱型玫瑰痤疮患者皮肤高频超声联合彩色多普勒血流成像的特征[J]. 中华皮肤科杂志, 2023, 56(6): 540-544. |
| [13] | 梁云生 黎展宏 伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558. |
| [14] | 张立明 肖汀. 慢性自发性荨麻疹的自身免疫发病机制研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 567-570. |
| [15] | 杨娜丽 许秋阳 吴含文 叶雅慧 朱吉玲 刘晶晶 李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524. |
|
